000			01973 a2200529 4500
005			20250516170531.0
264		0	_c20131211
008			201312s 0 0 eng d
022			_a1097-6744
024	7		_a10.1016/j.ahj.2013.05.013 _2doi
040			_aNLM _beng _cNLM
100	1		_aLincoff, A Michael
245	0	0	_aEvaluation of the dual peroxisome proliferator-activated receptor α/γ agonist aleglitazar to reduce cardiovascular events in patients with acute coronary syndrome and type 2 diabetes mellitus: rationale and design of the AleCardio trial. _h[electronic resource]
260			_bAmerican heart journal _cSep 2013
300			_a429-34 p. _bdigital
500			_aPublication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
650	0	4	_aAcute Coronary Syndrome _xcomplications
650	0	4	_aDiabetes Mellitus, Type 2 _xcomplications
650	0	4	_aDouble-Blind Method
650	0	4	_aFemale
650	0	4	_aHospitalization _xstatistics & numerical data
650	0	4	_aHumans
650	0	4	_aMale
650	0	4	_aMiddle Aged
650	0	4	_aMorbidity
650	0	4	_aMyocardial Infarction _xmortality
650	0	4	_aOxazoles _xtherapeutic use
650	0	4	_aPeroxisome Proliferator-Activated Receptors _xagonists
650	0	4	_aRisk Factors
650	0	4	_aStroke _xmortality
650	0	4	_aThiophenes _xtherapeutic use
650	0	4	_aTreatment Outcome
700	1		_aTardif, Jean-Claude
700	1		_aNeal, Bruce
700	1		_aNicholls, Stephen J
700	1		_aRydén, Lars
700	1		_aSchwartz, Gregory G
700	1		_aMalmberg, Klas
700	1		_aBuse, John B
700	1		_aHenry, Robert R
700	1		_aWedel, Hans
700	1		_aWeichert, Arlette
700	1		_aCannata, Ruth
700	1		_aGrobbee, Diederick E
773	0		_tAmerican heart journal _gvol. 166 _gno. 3 _gp. 429-34
856	4	0	_uhttps://doi.org/10.1016/j.ahj.2013.05.013 _zAvailable from publisher's website
999			_c23070782 _d23070782